This study is to evaluate the safety and technical performance of the Cardiovalve Transfemoral System for tricuspid valve replacement. Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

Start Date01 Feb 2024

Sponsor / Collaborator

Avania LLC

[+2]

NCT04409561

/ CompletedNot Applicable

A Study to Establish a Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

Start Date15 Nov 2021

Sponsor / Collaborator

Abionic SA

[+1]

NCT04312763

/ SuspendedNot Applicable

A Validation of the Functional Low-Vision Observer Rated Assessment (FLORA-20) for Profoundly Blind Individuals

This study aims to validate an observer-rated assessment titled "Functional Low-Vision Observer Rated Assessment (FLORA-20)", which comprises 20 functional vision tasks commonly performed in or around a blind individual's home environment. This study shall be carried out with individuals who have an implanted visual prosthesis device. There are no new implantations or changes to the original implant or external wearables being studied or tested. Additionally, data from the study shall not be used alter standard of care or the user's treatment options.

Start Date06 Mar 2020

Sponsor / Collaborator

Second Sight Medical Products, Inc.

[+1]

100 Clinical Results associated with Avania LLC

0 Patents (Medical) associated with Avania LLC

Literatures (Medical) associated with Avania LLC

01 Mar 2020·Molecular Genetics and MetabolismQ2 · BIOLOGY

5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics

Q2 · BIOLOGY

Article

Author: McIlduff, Mark ; DiBona, Kevin ; Hawthorne, Sarah ; Vockley, Jerry ; Baker, Jennifer L ; Lamppu, Diana ; Anastosoaie, Vera ; Seymour, Albert ; Kinch, Deborah ; Levy, Harvey ; Watling, Sharon ; Lindenberger, Jessica

BACKGROUNDPhenylketonuria (PKU) is an autosomal recessive disease caused by mutations in the PAH gene, resulting in deficiency of phenylalanine hydroxylase (PAH), an enzyme that converts phenylalanine (Phe) to tyrosine (Tyr). The purpose of this study was to capture real-world data associated with managing PKU under current standard of care and to characterize a representative population for a planned gene therapy trial.METHODSA retrospective chart review was conducted at two U.S. clinics for individuals 10-40 years old diagnosed with PKU-related hyperphenylalaninemia (HPA). Demographics, medical history, treatments and blood Phe data were collected from electronic medical records spanning a five-year period ending in November 2017.RESULTS152 patients were enrolled (65.8% had classical PKU). Although >95% of patients were prescribed a Phe-restricted diet, blood Phe concentrations remained substantially elevated, particularly in patients diagnosed with classical PKU. As the Phe threshold was lowered (Phe < 600, 360, 120 or 30 μmol/L), the number of patients with consecutive lab values below the threshold decreased, suggesting that many patients' Phe levels are inadequately controlled. 62.5% of patients were reported as having a history of at least one neuropsychiatric comorbidity, and adults were more likely than adolescents (69.5% vs. 54.3%). 92 of 98 PAH genotypes collected were distinct mutations; the 6 null-null genotypes were associated with classical PKU. Overall the demographics and clinical data were consistent across both sites.CONCLUSIONDespite dietary restrictions, mean Phe concentrations were > 360 μmol/L (a level considered well-controlled based on current U.S. treatment guidelines) for mild, moderate, and classical PKU patients. There remains an unmet need for therapies to control Phe concentrations.

01 Sep 2017·Pain physicianQ3 · MEDICINE

Serious Adverse Events Associated with Readmission Through One Year After Vertebral Augmentation with Either a Polyetheretherketone Implant or Balloon Kyphoplasty.

Q3 · MEDICINE

Article

Author: McIlduff, Mark ; Tutton, Sean ; Warner, Christopher ; Beall, Douglas P ; Coe, Jeffrey D ; Hornberger, John ; Bloch, Daniel

BACKGROUNDThe KAST (Kiva Safety and Efficacy) investigation device exempt (IDE) study indicated that the majority of patients responded equally well to vertebral augmentation using either an implant-based approach or balloon kyphoplasty (BK). Additional investigation has suggested that a subset of patients may benefit further by avoiding repeated readmissions due to serious adverse events (SAEs) if they receive one vertebral augmentation approach over another.OBJECTIVESThe primary aim was to assess the effect of 2 different augmentation procedures on readmission rates for SAEs.STUDY DESIGNThe KAST trial is a pivotal, multicenter, randomized, controlled trial conducted to evaluate an implant-based vertebral augmentation approach (implant) against BK. Post-hoc analysis was performed to evaluate SAEs and readmission rates.SETTINGTwenty-one sites in North America and Europe.METHODSThe treatment effect of vertebral implant versus BK on SAEs requiring unplanned readmission was evaluated by estimating the risk of SAEs associated with readmissions in KAST while controlling for key baseline covariates using multivariate Poisson regression modeling.RESULTSForty (27.8%) patients with implants had 69 SAEs associated with readmission compared to 44 (31.2%) patients with BK having 103 events. The risk for all SAEs leading to readmission was 34.4% lower with the implant than for BK (95% confidence interval = 11.1%, 51.7%; P < 0.01). Multivariate analysis showed that the risk of SAEs associated with readmission was decreased in subjects treated with the implant compared to BK, and increased in patients with prior histories of vertebral compression fractures (VCFs) or significant osteoporosis.LIMITATIONSThe power of the KIVA study was based on clinical efficacy criteria to meet FDA requirements and recommendations for equivalency or noninferiority. The primary endpoint in this post-hoc analysis is SAEs associated with readmissions; as a result, the sample size is underpowered, although the results remain significant.CONCLUSIONThe augmentation approaches compared here have similar pain relief and quality of life effects; the implant showed a lower risk of readmissions.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT01123512. Key words: Vertebral compression fracture, kiva implant, balloon kyphoplasty, vertebroplasty, health economics, osteoporosis.

01 Aug 2014·The Journal of Thoracic and Cardiovascular SurgeryQ1 · MEDICINE

SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement. Part II. Mitral valve

Q1 · MEDICINE

Review

Author: Mack, Michael J ; Hijazi, Ziyad M ; Trento, Alfredo ; Horlick, Eric ; Ruiz, Carlos E ; Feldman, Ted ; Bavaria, Joseph ; Miller, D Craig ; Mukherjee, Debabrata ; Cameron, Duke E ; Moon, Marc R ; Dean, Larry S ; Cigarroa, Joaquin E ; Weiner, Bonnie H ; Bacha, Emile A ; Zahn, Evan ; Tommaso, Carl L ; Aldea, Gabriel S ; Bolman, R Morton ; Fullerton, David A

Cardiac Catheterization Laboratory, North Shore Shore University Health System, 9669 North Ke 60076; Cardiothoracic Surgery, University of Colo Colorado 88045-2527; Cardiac Catheterization Hospital, Evanston, Illinois 60201; Cardiology Di pital, Walgreen Building 3rd Floor, Evanston, Illinoi Washington School of Medicine, Seattle, Washin Regional Heart Center, 1959 NE Pacific, Box 356171 98195; Rush Center for Congenital & Structural H Illinois 60612; Pediatric Cardiology, Rush Unive Chicago, Illinois 60612; Peter Munk Cardiac Cen Hospital, Toronto, Ontario M5G2C4; Saint Vincent Medical Center/Fallon Clinic, Worcester, Massach medical Associates, Northborough, Massachusetts; Center, Los Angeles, California 90048; Departmen Health & Science University, 2761 SW Patton Ct., Po Lenox Hill Heart and Vascular Institute of New York 10021; Division of Cardiothoracic Surgery, delphia, Pennsylvania 19104; Cardiovascular C Hospital Baylor Plano, Plano, Texas 75093; The Da Broccoli Center for Aortic Diseases, The John

News (Medical) associated with Avania LLC

06 Jan 2019

·www.businesswire.com

Factory CRO and Boston Biomedical Associates Announce Merger

BILTHOVEN, Netherlands & MARLBOROUGH, Mass.--([BUSINESS WIRE](https://www.businesswire.com/))--[Factory-CRO Group](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.factory-cro-group.com%2F&esheet=51921263&newsitemid=20190107005358&lan=en-US&anchor=Factory-CRO+Group&index=1&md5=a74d10620b79796a94b9fd7d7a6e7405), a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and [Boston Biomedical Associates](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bbacro.com%2F&esheet=51921263&newsitemid=20190107005358&lan=en-US&anchor=Boston+Biomedical+Associates&index=2&md5=0b1c27ba2098662444307e83311632ce) (BBA) a premier full-service Medical Device/Biotechnology CRO and Consultancy based in the United States announce that they have merged the organizations. > This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience. Now we are the only Medical Device and Medical Technology CRO that offers services in US, Eur, AU and NZ > > [Post this](https://www.businesswire.com/news/home/20190107005358/en/Factory-CRO-and-Boston-Biomedical-Associates-Announce-Merger#) The merger further advances the shared strategic vision to become the leading Global Medical Device and Medical Technology focused CRO. Following the recent acquisitions of MileStone Research Organization, Five Corners, and Clinical Device Group the Factory-CRO Group now has specialized operations and expertise in the United States, Australia/New Zealand, and Europe. This global expansion coupled with the diverse medical therapeutic expertise provides a means to efficiently service clients. “BBA is excited to join Factory-CRO’s worldwide group as it will allow us to expand our comprehensive service offering to our clients,” said Lauren Baker, PhD, President and CEO of BBA. “The alignment of Factory-CRO and BBA’s core values and approach to engagements combined with our collective therapeutic competencies ensures that our clients now have improved access to our global clinical trial execution resources, and our regulatory and medical expertise.” Dr. Baker then added, “We are able to fully support our clients as their needs evolve and they strive to help patients globally.” “We are honored to have the BBA team join the Factory-CRO Group,” said Dirk Meijer, MD, MSc,PhD, Factory-CRO CEO. “BBA’s ability to provide CRO/Consultative service in North America was a missing link in our global offerings.” Dr. Meijer then added, “Our clients have consistently asked us to expand our offerings in North America. This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience. Now we are the only Medical Device and Medical Technology CRO that offers services in United States, Europe, Australia and New Zealand. We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.” About Factory-CRO Group: Factory-CRO Group is a leading, full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics and device-drug combination products internationally. Founded in 1992, the business offers a full suite of trial management services to its global client base across a broad range of therapeutic areas, including orthopedic, cardiovascular, dermatology and aesthetics. Current members of Factory-CRO Group are: BBA, Five Corners CRO, Milestone Research group and Factory-CRO. For more information about Factory-CRO, visit their website, [www.factory-cro.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.factory-cro.com&esheet=51921263&newsitemid=20190107005358&lan=en-US&anchor=www.factory-cro.com&index=3&md5=a385daf580423d631e1ca6b4f827796c) or contact Joris Bannenberg, MD, PhD, Factory-CRO’s CMO: Joris Bannenberg, MD, PhD CMO [j.bannenberg@factory-cro.com](mailto:j.bannenberg@factory-cro.com) +31 30 229 2727 (x108) About Boston Biomedical Associates: Boston Biomedical Associates (BBA) is a premier full-service Medical Device/Biotechnology CRO and Consultancy firm. Founded in 2000, by Lauren Baker, Ph.D., this leading CRO has earned a reputation for its comprehensive approach to clinical trial execution services to its global client base across a broad range of therapeutic areas, including orthopedic, cardiovascular, endocrine and neurologic disorders. For more information about BBA, visit their website, [www.bbacro.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bbacro.com%2F&esheet=51921263&newsitemid=20190107005358&lan=en-US&anchor=www.bbacro.com&index=4&md5=ef4d7abacbf71afcadd4dd5ff825db47) or contact Mack Rubley, PhD, BBA’s Vice President of Business Development and Marketing: Mack D. Rubley, PhD VP, Business Development and Marketing 702-808-3494 [mrubley@bbacro.com](mailto:mrubley@bbacro.com)

Acquisition

100 Deals associated with Avania LLC

100 Translational Medicine associated with Avania LLC

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Amcasertib/Napabucasin ( STAT3 )	Neoplasms More	Phase 1
BBI-801	Neoplasms More	Preclinical
Amcasertib ( NANOG )	Hepatocellular Carcinoma More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis